Adamantanes have been used for the prophylaxis and treatment of Influenza A virus (IAV) infections worldwide. However, they have limited use because of increasing number of resistant viruses during recent years. In investigating the frequency of amantadine-resistant IAVs (H3N2) circulating in Iran in 2005-2008, we found that M2 sequences of recently circulating viruses that were amantadine-resistant contained a Ser31Asn mutation. Thus, adamantanes should not be used for treatment or prophylaxis of recent IAVs (H3N2) infections. In future, their potential use will depend on the resistance of circulating viruses.
CITATION STYLE
Yavarian, J., Mokhtari Azad, T., Shafiei Jandaghi, N. Z., & Nategh, R. (2009). Amantadine-resistant influenza A (H3N2) viruses in Iran. Acta Virologica, 53(2), 135–138. https://doi.org/10.4149/av_2009_02_135
Mendeley helps you to discover research relevant for your work.